Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital

被引：0
|
作者：
Patel, Devin N. [1 ]
Chapin, Brian F. [2 ]
Freedland, Stephen J. [1 ,3 ]
机构：
[1] Cedars Sinai Med Ctr, Div Urol, Los Angeles, CA 90048 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[3] Vet Affairs Med Ctr, Div Urol, Durham, NC 27705 USA
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2018年 / 25卷 / 12期
关键词：
D O I：
10.1111/iju.13861
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1005 / 1005
页数：1
相关论文
共 50 条
  • [11] The Association Between Radiographic Response and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Receiving Chemotherapy
    Sonpavde, Guru
    Pond, Gregory R.
    Berry, William R.
    de Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    Armstrong, Andrew J.
    CANCER, 2011, 117 (17) : 3963 - 3971
  • [12] Abiraterone increases overall survival in men with castration-resistant prostate cancer
    Annette Fenner
    Nature Reviews Urology, 2011, 8 (7) : 351 - 351
  • [13] Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy
    Sonpavde, G.
    Pond, G. R.
    Berry, W. R.
    De Wit, R.
    Eisenberger, M. A.
    Tannock, I.
    Armstrong, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [14] Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
    Halabi, Susan
    Dutta, Sandipan
    Tangen, Catherine M.
    Rosenthal, Mark
    Petrylak, Daniel P.
    Thompson, Ian M.
    Chi, Kim N.
    Araujo, John C.
    Logothetis, Christopher
    Quinn, David I.
    Fizazi, Karim
    Morris, Michael J.
    Eisenberger, Mario A.
    George, Daniel J.
    De Bono, Johann S.
    Higano, Celestia S.
    Tannock, Ian F.
    Small, Eric J.
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) : 403 - +
  • [15] Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer"
    van der Doelen, Maarten J.
    Slootbeek, Peter H. J.
    Mehra, Niven
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 395 - 396
  • [16] Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
    Small, E. J.
    Saad, F.
    Chowdhury, S.
    Oudard, S.
    Hadaschik, B. A.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Uemura, H.
    De Porre, P.
    Smith, A. A.
    Zhang, K.
    Lopez-Gitlitz, A.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1813 - 1820
  • [17] LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Wang, Wei
    Kwon, Young Suk
    Su, Lixiao
    Kim, Isaac Yi
    Lu, Shou-En
    JOURNAL OF UROLOGY, 2017, 197 (04): : E765 - E765
  • [18] Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) : 33 - 33
  • [19] Factors influencing survival in metastatic castration-resistant prostate cancer therapy
    Marchioni, Michele
    Marandino, Laura
    Amparore, Daniele
    Berardinelli, Francesco
    Mascitti, Marco
    Ferro, Matteo
    Campi, Riccardo
    Schips, Luigi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1061 - 1079
  • [20] Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2019, 201 (01): : 31 - 31
12345